Clinical characteristics of the first case treated with both delamanid and bedaquiline

Country of birthIndia
Age39 years
Body weight at diagnosis#65 kg
Case categoryRetreatment case
Number of previous anti-TB treatments4
Drugs administered in previous anti-TB treatmentsKanamycin 750 mg i.m. (12 months)
Levofloxacin 1 g, PAS 10 g, cycloserine 750 mg, ethionamide 750 mg, capreomycin 1 g i.m. (14 months)
High-dose isoniazid 900 mg, rifabutin 300 mg, clofazimine 200 mg, clarithromycin 1 g, amoxicillin/clavulanate 625 mg, terizidone 1 g three times daily, imipenem 500 mg i.v. three times daily (12 months), linezolid 600 mg then 300 mg
Previous outcomeCured (twice)
Body mass index at baseline26.9 kg·m−2
Bacteriology at baselineSputum smear positive
Culture positive
Xpert positive
At Day 18: smear negative
Culture taken after 28 days of treatment: ongoing (negative on the 14th day of MGIT culture)
RadiologyBilateral upper zones fibrocavitary lesions
Drug resistancesResistant to 12 drugs: Isoniazid, rifampicin, kanamycin, amikacin, capreomycin, moxifloxacin, ofloxacin, ethionamide, PAS, linezolid, high-dose isoniazid, high-dose moxifloxacin
Susceptible to: clofazimine
Last treatment regimenDelamanid, bedaquiline, clofazimine (200 mg), terizidone (1 g) and meropenem 1 g three times daily plus amoxicillin/clavulanate 1 g/200 mg three times daily i.v., all started on February 25, 2016Bedaquiline stopped on March 7, 2016, restarted March 12, 2016
  • TB: tuberculosis; PAS: para-aminosalicylic acid; i.m.: intramuscular; i.v.: intravenous; MGIT: mycobacteria growth indicator tube. #: August 31, 2015.